AUNA
AI MemoAuna
As of 2026-11-07/Confidence low
Data freshness
AI Memo
As of 2026-11-07 • Model: RankAlpha Sentiment Codex
Decision Panel
Action, confidence, horizon, and decision blockers at a glance.
Action
—
Confidence
low
Horizon
—
Key catalyst
Third-quarter results and Colombia contract review • 2026-11-17
Base target: $5 / p=45% prob
Biggest risk
The Colombia payor-contract cost pressure has already displaced expected 2026 adjusted EBITDA growth with broadly flat year-over-year performance. The magnitude and duration remain under company review. [#IR-2026-10-22] Company outlook
Invalidation
Break below $3 or thesis failure.
What would change my mind?
Higher preliminary surgery volumes across all three countries and Auna's expectation that revenue growth remains in line with prior guidance could support recovery if Colombia contract costs prove temporary. [#PR-EARNINGS-2026-10-15] [#IR-2026-10-22] Company outlook
Research note
Recommendation
—
Confidence
low
As of
2026-11-07
Base target
$5
p=45%
Bull target
$6
p=25%
Bear target
$3
p=30%
Key bullets
Fast scan of bull, bear, and watch items
BullKey bullets
- Surgery-volume gains versus oncology costs
- Centro Ambulatorio Trecca construction
- Higher preliminary surgery volumes across all three countries and Auna's expectation that revenue growth remains in line with prior guidance could support recovery if Colombia contract costs prove temporary.
BearKey bullets
- Auna has not yet completed its review of the contract's full-year adjusted EBITDA implications.
- [#IR-2026-10-22] Company outlook
- Trecca's projected late-2028 opening depends on construction execution and milestone payments.
WatchKey bullets
- Third-quarter results and Colombia contract review
Summary
High-level snapshot
Recommendation
-
Model confidence
low
Timeframe
-
Asset
Equity
Trigger
-
Base case: $5 (p=45%)
Target spread vs base: +30% / -26%
Scenario probabilities
Bull Target: $6 (p=25%)Base Target: $5 (p=45%)Bear Target: $3 (p=30%)
Commentary
The October 22 EBITDA outlook reduction dominates the available news despite favorable preliminary volume indicators. A measured announcement-day price reaction and post-guidance analyst revisions were not verified. Social, options, short-interest and employee measures are unavailable; zeroes in those fields mean missing data, not neutral readings. Low coverage and weak direct-peer comparability limit conviction.
As of 2026-11-07 • Updated bi-weekly / post-earningsSource: Internal modelMethodology
Analyst Summary
Thesis highlights from the latest analysis
Bull Case
Higher preliminary surgery volumes across all three countries and Auna's expectation that revenue growth remains in line with prior guidance could support recovery if Colombia contract costs prove temporary. [#PR-EARNINGS-2026-10-15] [#IR-2026-10-22] Company outlook
Bear Case
The Colombia payor-contract cost pressure has already displaced expected 2026 adjusted EBITDA growth with broadly flat year-over-year performance. The magnitude and duration remain under company review. [#IR-2026-10-22] Company outlook
Drivers
Scannable catalysts and supporting factors
- Surgery-volume gains versus oncology costs
- Centro Ambulatorio Trecca construction
Scenarios
Bull Target (Scenario probability)
$6 / p=25% prob
Base Target (Scenario probability)
$5 / p=45% prob
Bear Target (Scenario probability)
$3 / p=30% prob
Analysis 2026-11-07 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.
Sentiment & Exposure
News Sentiment (30d)
-0.40
Social Sentiment (7d)
0.00
Events
Other notable items detected
- EVENT2026-11-17Third-quarter results and Colombia contract reviewAuna scheduled its release for November 17 and call for November 18. The key test is whether it quantifies the duration and cost of the Colombia payor-contract pressure behind its reduction of expected 2026 adjusted EBITDA growth from the low end of 10%–14% FX-neutral to broadly flat year over year. [#IR-2026-10-13] Reporting dates [#IR-2026-10-22] Company outlookProb 95.00% • Move -8.00% • Priced-in 60.00%
Short-term Catalysts
Next few weeks
- Surgery-volume gains versus oncology costs2026-12-31Preliminary third-quarter surgery counts rose year over year in Mexico, Peru and Colombia, but Auna attributed its reduced EBITDA outlook to unexpected advanced-stage cancer costs under a Colombia payor contract. Whether volume growth offsets that pressure remains unproven. [#PR-EARNINGS-2026-10-15] [#IR-2026-10-22] Company outlookProb 55% • Move -5% • Priced-in 50%
Long-term Catalysts
Months to a year
- Centro Ambulatorio Trecca construction2028-12-31Auna says the conditions precedent to construction of its Peru public-private partnership have been fulfilled and projects operations in late 2028. Construction milestones and eventual returns remain execution questions, not near-term earnings support. [#IR-2026-10-21] Company announcementProb 60% • Move 8% • Priced-in 20%
Risks
- Auna has not yet completed its review of the contract's full-year adjusted EBITDA implications. [#IR-2026-10-22] Company outlook
- Trecca's projected late-2028 opening depends on construction execution and milestone payments. [#IR-2026-10-21] Company announcement
- Unexpected advanced-stage cancer costs under a Colombia payor contract may persist or spread beyond current assumptions. [#IR-2026-10-22] Company outlook
Peers
| Symbol | Summary |
|---|---|
| ABT | Broad healthcare-sector reference only. Its device and diagnostics businesses and much larger scale make it unsuitable as a direct valuation peer for Auna's Latin American healthcare-services and plan platform. |
| EMBC | Similar supplied market-cap range, but a medical-device business rather than a hospital and health-plan operator; not a direct valuation peer. |
Sources
Internal and external references used in this analysis
- Model source: RankAlpha Sentiment Codex
- Analysis date: 2026-11-07

